Immunic
IMUX
55 hedge funds and large institutions have $62.1M invested in Immunic in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 15 increasing their positions, 17 reducing their positions, and 8 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.18% less ownership
Funds ownership: 6.38% → 6.2% (-0.18%)
7% less funds holding
Funds holding: 59 → 55 (-4)
12% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 17
18% less capital invested
Capital invested by funds: $75.7M → $62.1M (-$13.7M)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
86% less call options, than puts
Call options by funds: $60K | Put options by funds: $419K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$430K |
| 2 |
JFG
Jefferies Financial Group
New York
|
+$412K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$353K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$145K |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$100K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.39M |
| 2 |
Renaissance Technologies
New York
|
-$567K |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$556K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$316K |
| 5 |
Two Sigma Advisers
New York
|
-$156K |
IMUX Hedge Fund Activity: Q2 2024 in Review
55 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q2 2024, worth a combined $62.1M — down 18% from $75.7M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of IMUX and 4 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 15 added.
The largest buyer was Vanguard Group, adding an estimated $430K. The largest seller was Ikarian Capital, cutting an estimated $1.39M.
- 55 institutional investors held Immunic (IMUX) as of Q2 2024, down from 59 in Q1 2024.
- Funds reported $62.1M of Immunic stock for Q2 2024, down 18% quarter-over-quarter.
- 4 funds opened new Immunic positions in Q2 2024 and 8 closed out, a net change of -4 holders.
- The largest Immunic buyer in Q2 2024 was Vanguard Group, an estimated $430K added.
- The largest Immunic seller in Q2 2024 was Ikarian Capital, an estimated $1.39M sold.
Based on aggregated 13F filings for Q2 2024.